Event chart VERTEX PHARMACEUTICALS INCORPORATED |
|
|
Upcoming events on VERTEX PHARMACEUTICALS INCORPORATED |
|
08/03/23 | | Q2 2023 Earnings Release (Projected) |
11/01/23 | | Q3 2023 Earnings Release (Projected) |
01/31/24 | | Q4 2023 Earnings Release (Projected) |
05/01/24 | | Q1 2024 Earnings Release (Projected) |
|
Past events on VERTEX PHARMACEUTICALS INCORPORATED |
|
05/17/23 | 09:00am | | Annual General Meeting |
05/09/23 | 12:20pm | | Bank of America Healthcare Conference |
05/01/23 | 04:30pm | | Q1 2023 Earnings Call |
05/01/23 | 04:01pm | | Q1 2023 Earnings Release |
03/07/23 | 02:50pm | | Cowen Health Care Conference |
02/07/23 | 04:30pm | | FY 2022 Earnings Call |
02/07/23 | 04:01pm | | FY 2022 Earnings Release |
01/09/23 | 11:15am | | JP Morgan Healthcare Conference |
12/13/22 | | American Society of Hematology Meeting - Abstract No. 4820 and 4882 |
12/11/22 | 01:00pm | | American Society of Hematology Meeting - Abstract No. 577 |
|
Past dividends on VERTEX PHARMACEUTICALS INCORPORATED |
|
- No events available -
|
|
Fiscal Period : December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
Sales M $ |
Released Forecast Spread | 3 048 2 992 1,9% | 4 163 3 759 11% | 6 206 6 159 0,76% | 7 574 7 502 0,97% | 8 931 8 933 -0,03% | 9 771 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 1 184 1 123 5,4% | 1 893 1 770 6,9% | 3 601 3 649 -1,3% | 4 470 4 490 -0,46% | 4 941 5 101 -3,1% | 4 905 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 112 1 052 5,7% | 1 786 1 609 11% | 3 491 3 471 0,58% | 4 344 4 345 -0,02% | 4 793 4 832 -0,81% | 4 691 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 600 771 -22% | 1 395 964 45% | 3 117 2 891 7,8% | 2 730 2 761 -1,1% | 4 232 4 155 1,9% | 4 326 |
Net income M $ |
Released Forecast Spread | 2 097 740 183% | 1 177 796 48% | 2 712 2 608 4,0% | 2 342 2 295 2,1% | 3 322 3 287 1,1% | 3 429 |
EPS $ |
Released Forecast Spread | 8,09 2,84 185% | 4,51 3,08 46% | 10,3 9,87 4,2% | 9,01 8,80 2,4% | 12,8 12,8 0,17% | 13,2 | Announcement Date | 02/05/2019 | 01/30/2020 | 02/01/2021 | 01/26/2022 | 02/07/2023 | - |
|
|
Fiscal Period : December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 |
Sales M $ |
Released Forecast Spread | 1 724 1 657 4,1% | 1 793 1 726 3,9% | 1 984 1 864 6,4% | 2 073 2 007 3,3% | 2 098 2 074 1,1% | 2 196 2 132 3,0% | 2 334 2 227 4,8% | 2 303 2 303 -0,01% | 2 375 2 336 1,7% | 2 421 | 2 457 | 2 511 | 2 494 | 2 545 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 003 921 8,8% | 1 029 949 8,5% | 1 188 1 041 14% | 1 124 1 126 -0,15% | 1 167 1 188 -1,8% | 1 187 1 179 0,67% | 1 289 1 210 6,6% | 1 150 1 197 -3,9% | 902 971 -7,1% | 1 248 | 1 257 | 1 257 | 1 306 | 1 325 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 821 759 8,2% | -44,3 188 -124% | 1 083 844 28% | 871 908 -4,1% | 955 995 -4,0% | 1 024 994 3,0% | 1 176 1 038 13% | 1 077 990 8,8% | 892 850 4,9% | 1 132 | 1 134 | 1 151 | 1 190 | 1 211 |
Net income M $ |
Released Forecast Spread | 653 615 6,1% | 66,9 110 -39% | 852 674 26% | 770 720 7,0% | 762 801 -4,8% | 811 799 1,5% | 931 820 13% | 819 779 5,1% | 700 677 3,4% | 897 | 910 | 914 | 959 | 976 |
EPS $ |
Released Forecast Spread | 2,49 2,29 8,7% | 0,26 0,69 -62% | 3,28 2,51 31% | 3,00 2,76 8,6% | 2,96 3,14 -5,6% | 3,13 3,07 2,0% | 3,59 3,27 9,9% | 3,15 3,09 1,9% | 2,69 2,67 0,78% | 3,45 | 3,45 | 3,42 | 3,56 | 3,61 | Announcement Date | 04/29/2021 | 07/29/2021 | 11/02/2021 | 01/26/2022 | 05/05/2022 | 08/04/2022 | 10/27/2022 | 02/07/2023 | 05/01/2023 | - | - | - | - | - | |
|
|
Upcoming sector events for VERTEX PHARMACEUTICALS INCORPORATED |
|
|
|
Past sector events for VERTEX PHARMACEUTICALS INCORPORATED |
|
|
|
|
|
|
Vertex Pharmaceuticals Incorporated : Confirms growth trajectory |
|
VERTEX PHARMACEUTICALS A very promising pipeline |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|